Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP

Average trade mark-up on these drugs now around 170%, reaching 700% in some cases; intervention to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients

from India Latest News: Top National Headlines Today & Breaking News | The Hindu https://ift.tt/djBv2M6